Definium Therapeutics (DFTX) Interest Expenses (2023 - 2026)

Definium Therapeutics (DFTX) has 4 years of Interest Expenses data on file, last reported at $1.2 million in Q1 2026.

• Interest Expenses for Q1 2026 came in at $1.2 million, up 99.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.1 million (up 148.8% YoY), and the FY2025 annual result was $5.5 million, up 140.91% from the prior year.
• Interest Expenses fell to $1.2 million in Q1 2026 per DFTX's latest filing, from $1.3 million in the prior quarter.
• Over five years, Interest Expenses peaked at $2.3 million in Q2 2025 and troughed at $51000.0 in Q3 2023.
• A 4-year average of $756615.4 and a median of $649000.0 in 2023 frame the typical range for Interest Expenses.
• On a YoY basis, Interest Expenses climbed as much as 1325.49% in 2024 and fell as far as 1.08% in 2024.
• A 4-year view of Interest Expenses shows it stood at $649000.0 in 2023, then increased by 1.08% to $656000.0 in 2024, then soared by 96.04% to $1.3 million in 2025, then dropped by 6.69% to $1.2 million in 2026.
• Business Quant data shows DFTX's Interest Expenses at $1.2 million in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.